Search

Zai Lab Ltd ADR

Gesloten

SectorGezondheidszorg

25.33 -3.17

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

26.15

Max

26.33

Belangrijke statistieken

By Trading Economics

Inkomsten

191K

-51M

Verkoop

6.7M

106M

EPS

-0.46

Winstmarge

-47.808

Werknemers

1,784

EBITDA

-2.1M

-46M

Aanbevelingen

By TipRanks

Aanbevelingen

Strong Buy

12 Maanden Prognose

+49.94% upside

Dividenden

By Acuity

Volgende Winsten

5 nov 2026

Marktinformatie

By TradingEconomics

Marktkapitalisatie

805M

2.9B

Vorige openingsprijs

28.5

Vorige sluitingsprijs

25.33

Nieuwssentiment

By Acuity

38%

62%

103 / 339 Rangschikking in Healthcare

Zai Lab Ltd ADR Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

7 sep 2026, 03:01 UTC

News

Bitcoin is trading lower today, despite Michael Saylor's prediction of a rise to $100,000. The asset remains above its 20-day moving average.

5 sep 2026, 00:05 UTC

News

Illumina Inc will join the S&P 500 on September 21, 2026. Shares are advancing in after-market hours following the announcement.

5 sep 2026, 00:05 UTC

News

Ionis Pharmaceuticals shares are lower in after-market hours following Novartis' announcement that the pelacarsen Phase 3 study did not meet its primary endpoint.

5 sep 2026, 00:01 UTC

News

Royalty Pharma PLC shares fell in after-market hours following the failed Phase 3 trial of pelacarsen, impacting its funding agreement with Ionis.

5 sep 2026, 00:01 UTC

Social Media
News

NIO shares are higher in after-market hours following a 69.1% revenue increase to approximately $4.74 billion and improved vehicle deliveries.

5 sep 2026, 00:01 UTC

News

Bloom Energy Corp will join the S&P 500 on September 21, 2026, boosting investor visibility. Shares are trading higher in after-market hours.

5 sep 2026, 00:01 UTC

News

Shares lower in after-market trading; Roth Capital targets $48.00.

5 sep 2026, 00:00 UTC

News

Campbell's Co shares increased in after-market trading following workforce cuts and price hikes aimed at improving profitability.

5 sep 2026, 00:00 UTC

News

DocuSign Inc reported stronger-than-expected second-quarter results but is trading lower in after-market hours, reflecting valuation concerns amid rising Treasury yields.

4 sep 2026, 23:40 UTC

News

DocuSign Inc. reported strong second-quarter results and raised guidance, yet shares are trading lower in after-market hours amid valuation concerns and economic context.

4 sep 2026, 23:35 UTC

News

AAP shares lower in after-market hours on analyst rating updates.

4 sep 2026, 23:27 UTC

News

Photronics Inc shares traded lower in after-market hours amid a securities class action lawsuit alleging fraud related to its product pipeline and demand stability.

4 sep 2026, 23:20 UTC

News

Monster Beverage appoints Matthew S. Burroughs as Chief Accounting Officer and Deputy CFO, with shares rising in after-market trading.

4 sep 2026, 23:10 UTC

News

Northrop Grumman was awarded a $508.49 million contract for flight test support by the U.S. Department of Defense, shares trading higher in after-market hours.

4 sep 2026, 23:05 UTC

News

Pomerantz LLP filed a class action lawsuit against Replimune Group Inc for alleged securities fraud, contributing to a decline in shares during after-market hours.

4 sep 2026, 23:02 UTC

News

Illumina Inc will join the S&P 500 index effective September 21, 2026, following an announcement by Dow Jones Indices. Shares are trading higher after the news.

4 sep 2026, 23:02 UTC

Social Media
News

Star Bulk Carriers announced a parallel listing on Euronext Athens and an equity offering. Shares are lower in after-market hours following the news.

4 sep 2026, 23:02 UTC

News

Ionis Pharmaceuticals shares declined in after-market trading following Novartis' announcement of the failed pelacarsen Phase 3 study to reduce cardiovascular events.

4 sep 2026, 23:00 UTC

News

Bloom Energy shares are higher in after-market trading following its inclusion in the S&P 500, effective September 21, 2026.

4 sep 2026, 23:00 UTC

News

FirstEnergy shares rise in after-market trading following Potomac Edison's $52.8 million rate adjustment proposal to enhance electric system reliability in Maryland.

4 sep 2026, 23:00 UTC

News

Campbell's Co announced a restructuring plan, cutting 13% of salaried jobs and closing two plants. Shares are trading higher in after-market hours.

4 sep 2026, 22:51 UTC

Correlated Moves
News

Shares rose in after-market trading amid strength in oil sector.

4 sep 2026, 20:08 UTC

News

Planet Fitness Inc. is facing a securities class action lawsuit alleging misleading statements on customer growth, contributing to a decline in its stock during Friday's session.

4 sep 2026, 20:08 UTC

News
Correlated Moves

Marten Transport Ltd shares are higher, supported by a broader transportation sector rally and an amended credit facility increasing the letters-of-credit sublimit to $50 million.

4 sep 2026, 20:08 UTC

News

Jefferies Financial Group's shares are higher as it maintains "buy" ratings and raises price targets for several banks, including Barclays and Lloyds.

4 sep 2026, 20:08 UTC

News

El Pollo Loco Holdings to participate in two investor conferences this month. Shares are trading higher, reflecting positive sentiment despite earlier session pullback.

4 sep 2026, 20:08 UTC

News

Intuitive Surgical shares declined to $365.21, marking a four-week low. Ongoing market challenges contributed to the stock's downward movement during the session.

4 sep 2026, 20:08 UTC

News
Social Media
Macro Event

McDonald's shares hit a 52-week low amid ongoing challenges, including high menu prices like $15 for an Egg McMuffin, reflecting a broader market decline.

4 sep 2026, 20:08 UTC

News

OrthoPediatrics Corp shares are lower amid broader market declines and selling pressure following a strong jobs report. A major shareholder's recent sale adds to negative sentiment.

4 sep 2026, 20:08 UTC

Social Media
Macro Event
News
Correlated Moves

Intel shares are higher as demand for CPUs surges, driven by AI workloads. Despite a price target cut to $92, investor sentiment remains positive.

Peer Vergelijking

Prijswijziging

Zai Lab Ltd ADR Prognose

Koersdoel

By TipRanks

49.94% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 39.33 USD  49.94%

Hoogste 45 USD

Laagste 36 USD

Gebaseerd op 3 Wall Street-analisten die 12-maands prijsdoelen bieden voor Zai Lab Ltd ADR - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

3 ratings

3

Buy

0

Hold

0

Sell

Sentiment

By Acuity

103 / 339 Rangschikking in Gezondheidszorg

Nieuwssentiment

Bullish Bewijs

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Onder gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Zai Lab Ltd ADR

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis. The company also develops Tumor Treating Fields, a portable device for delivery of electric fields; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naïve- or -pretreated cancer patients; Tisotumab vedotin, an antibody drug conjugate; Adagrasib for treating KRAS-G12C-mutated NSCLC, colorectal cancer, and pancreatic cancer; and Bemarituzumab to treat gastric and gastroesophageal junction cancer patients. In addition, it develops Sulbactam/durlobactam, a combination of a beta-lactam antibiotic and a beta-lactamase inhibitor for the treatment of serious infections caused by Acinetobacter; KarXT for the treatment of psychiatric and neurological conditions. It has license and collaboration agreement with Tesaro, Inc. to develop, manufacture, and commercialize niraparib; NovoCure to develop and commercialize Tumor Treating Fields; Deciphera to develop and commercialize ripretinib; Paratek Bermuda Ltd. to develop, manufacture, and commercialize omadacycline; argenx, to develop and commercialize efgartigimod; BMS to develop and commercialize tisotumab vedotin and repotrectinib; Mirati to research, develop, manufacture, and commercialize adagrasib; Amgen to develop and commercialize bemarituzumab; and Innoviva to develop and commercialize Sulbactam-Durlobactam; Karuna to develop and commercialize KarXT; and strategic collaboration with Pfizer for XACDURO. The company was incorporated in 2013 and is headquartered in Shanghai, China.
help-icon Live chat